Scott E. Wolkenberg

Scott E. Wolkenberg

Auto-generated profile, based on publicly available information

Scott E. Wolkenberg

Discovery Chemistry, Janssen Research & Development LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2004 in Organic Letters
Verified
Journal Article
Closed access
SWScott E. Wolkenberg
Scott E. Wolkenberg
DWDavid D. Wisnoski
David D. Wisnoski
WLWilliam H. Leister
William H. Leister
YWYi Wang
Yi Wang
ZZZhijian Zhao
Zhijian Zhao
CLCraig W. Lindsley
Craig W. Lindsley

20 June 2022 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CHCharles E. Hendrick
Charles E. Hendrick
JJJeff R. Jorgensen
Jeff R. Jorgensen
CCCharu Chaudhry
Charu Chaudhry
ISIulia I. Strambeanu
Iulia I. Strambeanu
JBJean-Francois Brazeau
Jean-Francois Brazeau
SWScott E. Wolkenberg
Scott E. Wolkenberg

11 February 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CRChristopher A. Reiher
Christopher A. Reiher
DSDavid P. Schuman
David P. Schuman
NSNicholas Simmons
Nicholas Simmons
SWScott E. Wolkenberg
Scott E. Wolkenberg

26 January 2015 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SHScott T. Harrison
Scott T. Harrison
MPMichael S. Poslusney
Michael S. Poslusney
JMJames J. Mulhearn
James J. Mulhearn
ZZZhijian Zhao
Zhijian Zhao
NKNathan R. Kett
Nathan R. Kett
JBJames Barrow
James Barrow

22 May 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
WLWei Liu
Wei Liu
JMJames Mulhearn
James Mulhearn
BHBo Hao
Bo Hao
SCSantiago Cañellas
Santiago Cañellas
SLStefaan Last
Stefaan Last
SWScott E. Wolkenberg
Scott E. Wolkenberg

1 February 2010 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SWScott E. Wolkenberg
Scott E. Wolkenberg
CSCyrille Sur
Cyrille Sur
The simple amino acid glycine is implicated in both inhibitory and excitatory neurotransmission in mammalian central nervous system, and it modulates excitatory neurotransmission through its role as a necessary co-agonist for glutamatergic N-methyl-D-aspartate (NMDA) receptors. Given the involvement of NMDA receptor-mediated neurotransmission in complex cerebral processes such as cognition, pharmacological manipulation of extracellular synaptic glycine biology is an active area of pharmaceutical research to develop novel treatments for neuropsychiatric disorders. A key component of cerebral glycine metabolism is the glycine transporter type 1 (GlyT1) and elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. The present article will review the wealth of scientific evidence supporting that hypothesis and the medicinal chemistry effort by many pharmaceutical companies and academic institutions to develop potent and selective GlyT1 inhibitors.